ArticleBMC medical imaging2026
Visceral adiposity as a key predictor of metabolic dysfunction-associated steatotic liver disease: an analytical cross-sectional study in a tertiary care hospital of Karachi, Pakistan.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe burden of metabolic dysfunction-associated steatotic liver disease (MASLD) spectrum, beginning with hepatic steatosis, requires prompt diagnosis to improve prognostic outcomes. This study aims to assess central obesity measures, including visceral fat area (VFA), subcutaneous fat area (SFA), and waist circumference (WC), along with components of metabolic syndrome, to predict the presence of hepatic steatosis (MASLD).
methodsThis analytical cross-sectional study was conducted at a tertiary care hospital in Karachi, Pakistan. All participants aged above 18 years who underwent an unenhanced CT abdomen examination and had relevant blood workup were enrolled. Purposive sampling was used to select participants based on predefined eligibility criteria. Data was collected using a structured questionnaire to assess predictors and MASLD status among study participants. Descriptive statistics were used, and multiple logistic regression was performed to report the prevalence odds ratio with a 95% confidence interval. ROC curve analysis was conducted for VFA and triglycerides. AUC with 95% confidence interval, sensitivity and specificity were reported for these predictors. All the analysis was conducted on SPSS version 19.
resultsA total of 162 patients’ data was analyzed. MASLD was present in 83 patients (51.2%). The prevalence odds of visceral fat adiposity among patients with MASLD was 1.01 times compared to patients with healthy liver (P-value < 0.001). Additionally, body mass index (P-value 0.01), triglyceride levels (P-value 0.01) and superficial fat adiposity (P-value < 0.001) were all significantly associated with the presence of MASLD. The multiple logistic regression model included VFA (P-value < 0.001) and triglyceride levels (P-value 0.05) as a significant predictor for the presence of MASLD. Furthermore, VFA has an AUC of 0.69 (95% confidence interval: 0.61–0.77) with sensitivity 66.27% and specificity 62.03%, while triglycerides have an AUC 0.61 (95% confidence interval: 0.52–0.69) with sensitivity 59.04% and specificity 63.29%.
conclusionIn conclusion visceral fat adiposity and serum triglycerides are predictors of fatty changes seen in the liver. Larger population-based studies are recommended to develop cut-offs for visceral fat adiposity as a reliable screening tool for categorizing obesity and its potential complications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.